View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 28, 2021

Coronavirus company news summary: Oxford Immunotec Covid-19 test used in UK Com-COV Clinical Trial – Beroni Group’s SARS-CoV-2 antigen test kit secures export authorisation

By Chloe Kent

Oxford Immunotec has announced that its T-SPOT® Discovery SARS-CoV-2 kit will be utilised in the UK Com-COV clinical trial to evaluate T-cell immune response in people administered with two different approved Covid-19 vaccines as the first and second doses during vaccination. The clinical trial is being conducted in collaboration with the Oxford Vaccine Group and funded by the UK Vaccine Task Force and the National Institute for Health Research (NIHR).

Mobilus Health, a US-based mobile rapid molecular testing solutions provider, has developed the Mobilus DX Laboratory, a turnkey mobile testing solution, to support rapid Covid-19 molecular testing in medically underserved communities, schools, municipalities, and private companies. The first Mobilus DX Laboratory was procured by a CLIA lab based in Georgia. The laboratory utilises patented real-time multiplex technology to reduce the turnaround time for testing as it runs an RNA extraction free testing platform.

Beroni Group, an Australia-based diversified biopharmaceutical enterprise, has received export authorisation for its SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method). The test kit provides Covid-19 test results within ten minutes. The test kit has previously secured the CE mark for distribution in the European Union markets.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU